A new ambition for crosssector collaboration with the life sciences industry to support NHS sustainability and transformation – NHS Confederation

The NHS must be an active participant with industry in delivering the shared objective of outstanding patient outcomes. In part that is because it is a monopoly purchaser but also because the NHS should be where innovative products are developed

National Survey Of Local Innovation And Research Needs Of The NHS: Full Report – The AHSN Network

This report includes analysis of the innovation and research needs at local level across all Academic Health Science Networks. There were some differences in regional priorities but common themes emerged which reflected wider challenges facing the NHS and align with

Involving Patients and Carers in Quality Improvement Projects: A Practical Guide – Central and North West London NHS Foundation Trust

This guide explains how to involve patients and carers in Quality Improvement (QI) projects. The toolkit covers topics such as: How to pay service users and carers How to recruit service users and carers How to run effective and inclusive meetings

Legal Barriers to the Better Use of Health Data to Deliver Pharmaceutical Innovation – Office for Health Economics

This report summarise research evaluating the main legal barriers to the better use of health data for pharmaceutical innovation. Issues are evaluated according to barriers arising in utilising data to support key activities across the lifecycle of a medicine: epidemiology

Innovation in AMR: patent trends for novel diagnostics – Nesta

Research into patents and connected patent families using keywords relevant to point-of-care (POC) diagnostic tests for addressing antimicrobial resistance. This research analysed what patents are being filed and therefore what technology is being developed. The report assesses the implications on

Seven principles for public engagement in research and innovation policymaking: A guide from Nesta’s Inclusive Innovation team – Nesta

Why should researchers, innovators and those whose jobs it is to regulate technology engage with people who aren’t like them on topics like research and innovation? To give those in power a broader range of potential futures to aspire to

Ensuring access to medicines: How to stimulate innovation to meet patients’ needs?: (Policy Brief 29) – European Observatory on Health Systems and Policies

Brief that aims to inform discussions about stimulating more meaningful productivity in terms of pharmaceutical R&D. More specifically, it explores how R&D efforts can be steered to areas of unmet clinical needs and how efficiency in the R&D process can

Research integrity: clinical trials transparency: Tenth Report of Session 2017–19 Report, together with formal minutes relating to the report – House of Commons Science and Technology Committee

Selective non-publication of the results of research distorts the published evidence base and is a threat to research integrity. In the case of clinical trials, non-publication of results means that information on the efficacy of new drugs or other medical

World Alzheimer Report 2018: The State Of The Art Of Dementia Research: New Frontiers – Alzheimer’s Disease International

Alzheimer’s Disease International report that looks at a broad cross section of research areas including basic science; diagnosis; drug discovery; risk reduction and epidemiology. With the continued absence of a disease modifying treatment, the report also features progress, innovation and developments

2010 Year of Health and Wellbeing Evaluation Report – Liverpool Primary Care Trust

Report that evaluates a joint working approach to public health.  Key outcomes of this approach were that it: publicly articulates the solidarity between key agencies to working collaboratively with all partners and communities. provides a strong framework for partnership working across

R&D, Competition and Diffusion of Innovation in the EU: The Case of Hepatitis C: (Research Paper 18/06) – Office of Health Economics

Report analysing the functioning of a specific market for innovative treatments, Direct Acting Antivirals (DAAs) for hepatitis C virus (HCV), in six European countries. It explores the potential for in-class competition for DAAs to offset innovators’ market power and maximise the social welfare

Evidence synthesis for policy: A statement of principles – Royal Society and Academy of Medical Sciences

Evidence synthesis supports well-founded policymaking and public debate. The common question ‘What is the evidence for that?’ could be usefully rephrased as ‘Has sufficient synthesis of the evidence been done in relation to that?’. While typically asked in the former way, it is really the